Research
PREDICT-Meso Network members carry out a range of basic and translational research studies to help improve our understanding of mesothelioma. These include genomics, epigenomics, transcriptomics, immune landscape, proteomics, breathomics, target drug validation and risk profiling.
As the Network progresses, we will post details of studies and projects, their results and impact, and how to get involved in mesothelioma research in the sections below:
Meso-ORIGINS
Mesothelioma Observational study of RIsk prediction and Generation of benign-meso tissue pairs, Including a Nested MRI Sub-study
Meso-ORIGINS forms the prospective tissue collection element of the PREDICT-Meso International Accelerator Network. This study received West of Scotland Research Ethics Committee approval in October 2021 (REC ref 21/WS/0120).
Our aim is to generate a large prospective cohort of asbestos-exposed patients with benign initial biopsies that we can retrieve and then match to any subsequent samples acquired at mesothelioma evolution. These samples will be used in downstream pre-clinical work packages to define the biology driving mesothelioma evolution, define new drug targets and validate these in a suite of pre-clinical models generated using the same material. By the end of the 6-year PREDICT-Meso program we aim to have drug-target combinations ready for human trials.
Arm A
Arm A will recruit asbestos-exposed participants with benign initial pleural biopsies. Study activities include:
- Retrieval of the initial benign pleural tissue biopsies
- 2 year follow up, with collection of repeat biopsies in patients who develop Pleural Mesothelioma (PM) during this period and a proportion of patients with at least 18 months of benign follow-up. Blood samples and associated imaging will also be collected.
- Baseline collection of blood and breath (+/-MRI in sites recruiting the sub-study (see below)). This data will be used for for risk profiling – helping us to design future studies of early intervention in those at high-risk of mesothelioma evolution
Arm A MRI Sub-Study
Perfusion MRI can identify the earliest stages of PM with >90% sensitivity and specificity, including in patients with only minimal pleural thickening. Patients will be recruited from within Arm A at centres participating in the MRI sub-study (estimated ~10-12 sites).
Potentially eligible patients will be identified during the first visit in Arm A and invited back within 2 weeks for a contrast-enhanced MRI. This is a one-time additional visit. Participants will then continue on the Arm A pathway as above.
Arm B
A characteristic of PM is that multiple tumours can exist in different areas of pleural space and these may progress at different rates (spatial and temporal heterogeneity). In between there may be areas of benign pleural inflammation that does not progress to malignancy at all. Arm B will recruit patients with suspected but unconfirmed PM, allowing consent for multi-region dedicated research biopsies to be received prior to Thoracoscopy (LAT or VATS). These samples will carefully be carefully labelled and subjected to multiomic characterisation in order to better understand heterogeneity and its impact on subsequent progression and outcome.
Remote Observation
Patients who do not wish to take part Arm A will be offered the option to consent to remote observation. This will allow the study team to remotely collect of samples of blood, pleural fluid and pleural tissue that are taken as part of routine care but requires no active involvement from the patient.
Meso-ORIGINS open sites
| Site | Locations |
| NHS Grampian | Aberdeen Royal Infirmary |
| Blackpool Teaching Hospitals NHS Foundation Trust | Blackpool Victoria Hospital |
| North Bristol NHS Trust | Southmead Hospital |
| NHS Tayside | Ninewells Hospital |
| NHS Greater Glasgow and Clyde | Queen Elizabeth University Hospital; Glasgow Royal Infirmary; Gartnavel General Hospital |
| NHS Golden Jubilee | Golden Jubilee National Hospital |
| NHS Highlands and Islands | Raigmore Hospital |
| Kettering General Hospital NHS | Kettering General Hospital |
| University Hospitals of Leicester NHS Trust | Glenfield Hospital |
| NHS Lothian | Western General Hospital |
| Manchester University NHS Foundation Trust | Wythenshawe Hospital |
| University Hospitals of Morecambe Bay NHS Foundation Trust | Royal Lancaster Infirmary; Furness General Hospital |
| Newcastle upon Tyne Hospitals NHS Foundation Trust | Freeman Hospital |
| Aneurin Bevan University Health Board | Royal Gwent Hospital; St Woolos Hospital; Grange University Hospital |
| Northumbria Healthcare NHS Foundation Trust | North Tyneside General Hospital |
| Oxford University Hospitals NHS Foundation Trust | Churchill Hospital |
| Royal Papworth Hospital NHS Foundation Trust | Royal Papworth Hospital |
| University Hospitals Plymouth NHS Trust | Derriford Hospital |
| Northern Care Alliance NHS Foundation Trust | Salford Royal Hospital |
| Somerset Partnership NHS Foundation Trust | Musgrove Park Hospital |
| Sites in set up |
| Liverpool University Hospitals NHS Foundation Trust |
| North Tees and Hartlepool NHS Foundation Trust |
| Portsmouth Hospitals NHS Trust |
| Sheffield Teaching Hospitals NHS Foundation Trust |
| South Tyneside and Sunderland NHS Foundation Trust |
| University Hospitals of North Midlands NHS Trust |
Meso-ORIGINS
Get Involved
If you are interested in becoming a Meso-ORIGINS site, please contact PREDICT-Meso@glasgow.ac.uk for more information and a site capacity and capability form.
Meso-ORIGINS is an observational sampling study. Participants will be identified then followed up in parallel to routine clinical visits to see if there has been any evidence of mesothelioma evolution. The study has 2 arms (A and B). Arm A also includes a MRI sub-study and a remote observation option.
To be considered as a Meso- ORIGINS site, your site must be able to adhere to the following:
Arm A
Arm A will recruit asbestos-exposed participants with evidence of associated benign pleural disease based either on an initial pleural biopsy (of any form) or imaging within the last 1 year. Participants will be identified at outpatient clinic appointments, inpatient reviews, MDTs or via Arm B (see below).
A member of the research team will approach the participant, explain the study and provide a Participant Information Sheet (PIS) and consent form. Once consent has been accepted, participants will have baseline data recorded, their initial biopsies banked and non-invasive risk profiling tests performed. These will include a blood sample, an exhaled breath sample (+/- an MRI scan in participating centres, see MRI sub-study detail below). Pleural fluid samples will also be collected if patient has an indwelling pleural catheter (IPC) in-situ – it is acknowledged that not all patients will have an IPC.
Participants will then have regular study follow-up visit (every 6 months) for 2-years, ideally combined with routine clinical follow- up. A contrast- enhanced CT of the thorax should occur within 1-month of each follow-up visit, at which time blood sampling and follow-up data will be collected. A proportion of participants with at least 18-months of benign clinical follow-up (no clinical suspicion of mesothelioma) will also be invited by the site PI to have repeat biopsies for research purposes, if this is technically feasible based on ultrasound scanning, and acceptable to the participant. Participation in Arm A will end after 2-years follow up.
Arm A MRI Sub-Study
Potentially eligible patients will be identified during the first visit in Arm A, at which time an additional MRI sub-study PIS will be provided. Documentation of additional consent on a separate form is required as this is an additional voluntary element. The participant will be invited back within 2 weeks for a contrast-enhanced MRI in addition to completing a MRI safety questionnaire. This is a one-time additional visit. Participants will then continue on the Arm A pathway as above.
Arm B
Arm B will recruit eligible participants with suspected but unconfirmed MPM, prior to biopsy by thoracoscopy. Participants will be identified via urgent suspicion of cancer (USOC)/2-week wait urgent referral pathways. A member of the research team will approach the participant, explain the study, and provide a PIS and consent from. Following receipt of consent, thoracoscopy will be arranged – both LAT and VATS are acceptable in this arm. At LAT or VATS, multi-region research biopsies will be taken and carefully labelled. Pleural fluid will also be collected alongside clinically indicated diagnostic samples.
The participant will return within 2 weeks for clinical review and biopsy results discussion. Participation in Arm B will end after this visit.
However, Patients with benign pleural biopsies may be directed to the Arm A, although this is not mandatory. Note that a separate consent process for Arm a will be required.
If MPM is confirmed, they may be directed to the ASSESS-Meso study (a sister study within PREDICT-Meso) if this is open at site. ASSESS-Meso is a longitudinal observational study following patients with Mesothelioma (REC approval 17/SW/0019). More details can be found here.
Remote Observation
Patients who do not wish to take part in Arm A will be offered the option to consent to remote observation. This will allow the study team to remotely collect surplus of samples of blood, pleural fluid and pleural biopsies that are taken within routine care, but requires no active involvement from the patient. Participation in remote observation will end after 2 years follow up.
Meso-ORIGINS can now be found on the CRUK website under their 'find a clinical trial' search for those interested in Mesothelioma
Click the button below to go to this page and view an easy to read lay summary of the Meso-ORIGINS study